Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Marte Karen Brattås, Håkon Reikvam, Tor Henrik Anderson Tvedt & Øystein Bruserud. (2019) Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development 4:5, pages 263-274.
Read now
Read now
Abdallah Abou Zahr & Gautam Borthakur. (2017) Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opinion on Emerging Drugs 22:2, pages 137-148.
Read now
Read now
Håkon Reikvam, Tuyen Thi van Hoang & Øystein Bruserud. (2015) Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. Expert Review of Hematology 8:3, pages 315-327.
Read now
Read now
Håkon Reikvam, Michelle Hauge, Annette K Brenner, Kimberley Joanne Hatfield & Øystein Bruserud. (2015) Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology 8:3, pages 299-313.
Read now
Read now
Øystein Bruserud, Ina Nepstad, Michelle Hauge, Kimberley Joanne Hatfield & Håkon Reikvam. (2015) STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Review of Hematology 8:1, pages 29-41.
Read now
Read now
Kimberley Joanne Hatfield, Håkon Reikvam & Øystein Bruserud. (2014) Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert Opinion on Therapeutic Targets 18:11, pages 1237-1251.
Read now
Read now
Antonino Maria Spartà, Daniela Bressanin, Francesca Chiarini, Annalisa Lonetti, Alessandra Cappellini, Cecilia Evangelisti, Camilla Evangelisti, Fraia Melchionda, Andrea Pession, Alice Bertaina, Franco Locatelli, James A McCubrey & Alberto M Martelli. (2014) Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle 13:14, pages 2237-2247.
Read now
Read now
Håkon Reikvam, Ina Nepstad & Jerome Tamburini. (2013) Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity. Expert Opinion on Investigational Drugs 22:11, pages 1365-1370.
Read now
Read now
Alice C Fan, Jennifer J O'Rourke, Dave R Praharaj & Dean W Felsher. (2013) Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opinion on Investigational Drugs 22:11, pages 1495-1509.
Read now
Read now
Articles from other publishers (11)
Maria Hernandez-Valladares, Elise Aasebø, Frode Berven, Frode Selheim & Øystein Bruserud. (2020) Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging 12:24, pages 24734-24777.
Crossref
Crossref
Violeta Carmona‐Martínez, Antonio J. Ruiz‐Alcaraz, María Vera, Antonio Guirado, María Martínez‐Esparza & Pilar García‐Peñarrubia. (2018) Therapeutic potential of pteridine derivatives: A comprehensive review. Medicinal Research Reviews 39:2, pages 461-516.
Crossref
Crossref
Wen-Jie Lu, Wen Peng, Qian-Qian Sun, Yong-Huai Li, Bo Chen, Luo-Ting Yu, You-Zhi Xu, Si-Ying Wang & Ying-Lan Zhao. (2018) #2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models. Cell Death Discovery 4:1.
Crossref
Crossref
Bhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, Xiaokui Mo, Donna Bucci, Alison Walker, Rebecca Klisovic, Bhavana Bhatnagar, Katherine Walsh, Bjoern Rueter, Irene C. Waizenegger, Karl-Heinz Heider, William Blum, Sumithira Vasu & Natarajan Muthusamy. (2018) Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget 9:11, pages 9706-9713.
Crossref
Crossref
Håkon Reikvam, Ida-Sofie Grønningsæter, Knut Anders Mosevoll, Roald Lindås, Kimberley Hatfield & Øystein Bruserud. (2018) Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. Frontiers in Immunology 8.
Crossref
Crossref
Claudia Münch, Diana Dragoi, Anna-Verena Frey, Katja Thurig, Michael Lübbert, Ralph Wäsch, Lioudmila Bogatyreva, Dieter Hauschke, Silke Lassmann, Martin Werner & Annette M. May. (2015) Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leukemia Research 39:4, pages 462-470.
Crossref
Crossref
Dorothea Rudolph, Maria Antonietta Impagnatiello, Claudia Blaukopf, Christoph Sommer, Daniel W. Gerlich, Mareike Roth, Ulrike Tontsch-Grunt, Andreas Wernitznig, Fabio Savarese, Marco H. Hofmann, Christoph Albrecht, Lena Geiselmann, Markus Reschke, Pilar Garin-Chesa, Johannes Zuber, Jürgen Moll, Günther R. Adolf & Norbert Kraut. (2015) Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics 352:3, pages 579-589.
Crossref
Crossref
Na-Na Wang, Zhi-Heng Li, He Zhao, Yan-Fang Tao, Li-Xiao Xu, Jun Lu, Lan Cao, Xiao-Juan Du, Li-Chao Sun, Wen-Li Zhao, Pei-Fang Xiao, Fang Fang, Guang-Hao Su, Yan-Hong Li, Gang Li, Yi-Ping Li, Yun-Yun Xu, Hui-Ting Zhou, Yi Wu, Mei-Fang Jin, Lin Liu, Jian Ni, Jian Wang, Shao-Yan Hu, Xue-Ming Zhu, Xing Feng & Jian Pan. (2015) Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells. International Journal of Molecular Sciences 16:1, pages 1266-1292.
Crossref
Crossref
B T Gjertsen & P Schöffski. (2014) Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29:1, pages 11-19.
Crossref
Crossref
Annette Brenner, Håkon Reikvam, Antonio Lavecchia & Øystein Bruserud. (2014) Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms. Molecules 19:11, pages 18414-18447.
Crossref
Crossref
Alessia Casolaro, Josee Golay, Clara Albanese, Roberta Ceruti, Veronica Patton, Sabrina Cribioli, Alice Pezzoni, Marco Losa, Gemma Texido, Ursula Giussani, Francesco Marchesi, Nadia Amboldi, Barbara Valsasina, Silvia Bungaro, Gianni Cazzaniga, Alessandro Rambaldi, Martino Introna, Enrico Pesenti & Rachele Alzani. (2013) The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. PLoS ONE 8:3, pages e58424.
Crossref
Crossref